^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Soft Tissue Sarcoma
    Drug:Tazverik (tazemetostat) (EZH2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    TAZVERIK is a methyltransferase inhibitor indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Epithelioid Sarcoma: Preferred regimens...Tazemetostat